BiomimX
PrivateLast Round
Grant
Dec 6, 2023
Total Funding Raised
$976,000
Company Overview
BiomimX operates in Healthcare & Life Sciences and is based in Milan. Its latest recorded funding round was a Grant round in December 2023.
BiomimX Srl is a biotechnology company that is a pioneer in Organ-on-a-Chip (OoC) technology, producing the next generation of clinically relevant in-vitro models for pharmaceutical drug discovery and development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BiomimX Comparables
Compare BiomimX with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AlveoliX AG | 90% | |
| React4Life | 90% | |
| DLOC Biosystems | 89% |
For institutional investors. Book with your work email.
BiomimX Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 6, 2023 | ||||
| Accelerator | Oct 20, 2022 | ||||
| Grant | Mar 3, 2022 | ||||
| Grant | Mar 1, 2022 | ||||
| Grant | May 20, 2021 | ||||
Grant | May 1, 2021 |
For institutional investors. Book with your work email.
BiomimX Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Berkeley SkyDeck Europe, Milano | Accelerator |
| Berkeley SkyDeck | Accelerator |
| Camera di Commercio di Milano Monza Brianza Lodi | Grant |
| EIT Health | Grant |
| Swiss National Science Foundation | Grant |
| Invitalia | Grant |
| Berkeley SkyDeck Europe, Milan | Accelerator |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 598% MoM.
- May 20, 2026
Monthly visitors grew 97% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 27, 2026
In Aug '26, BiomimX S.r.l. is developing a miniature model of living human heart tissue in the United Kingdom with support from Innovate UK's £2 million funding for alternatives to animal testing.
For institutional investors. Book with your work email.
BiomimX Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BiomimX's valuation, stock price, and market status.
Is BiomimX a public or private company?
BiomimX is a private company.
What is the current stock price of BiomimX?
BiomimX is a private company, so its shares have no public market price. Caplight tracks BiomimX's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BiomimX worth (valuation)?
Valuation information for BiomimX is not publicly available.
Can I buy BiomimX stock?
BiomimX shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BiomimX's last funding round?
BiomimX's most recent funding round was Grant on December 6, 2023.
Who are the main investors in BiomimX?
Key investors in BiomimX include Berkeley SkyDeck Europe, Milano, Berkeley SkyDeck, Camera di Commercio di Milano Monza Brianza Lodi, EIT Health, Swiss National Science Foundation.
Will BiomimX IPO soon?
No public IPO plans have been announced for BiomimX.
How can I track BiomimX secondary market activity?
Caplight tracks bids, offers, and trades in BiomimX's shares on secondary markets.